The Effectiveness of Ivermectin on the Risk of Mortality in COVID-19 Patients: A Meta Analysis

Background: The Coronavirus Disease 2019 (COVID-19) has become the highest priority of global pandemic. New and repurposed drugs are being tested on mild to moderate levels of COVID-19 to help suppress transmission of the virus. Ivermectin is one of the repurposed drugs with known safety records with more than 2.5 billion doses dispensed in the past. This study aims to estimate the effectiveness of ivermectin in reducing the risk of mortality in COVID-19 patients based on the results of a number of previous similar studies.Subjects and Method: This study is a systematic review and meta-analysis. This study used secondary data in the form of data from previous study results. A systematic and comprehensive database search was carried out through several databases including: PubMed, Science Direct, Google Scholar, and Springer Link. Analysis of this study was using RevMan 5.3 software. This study used the eligibility criteria with the PICO model, populations: covid-19 patients, intervention: ivermectin administration, comparison: patients without ivermectin, outcome: mortality in COVID-19 patients. The inclusion criteria used were full paper in English and Indonesian with a randomized controlled trial, including the number of deaths, and the primary study was conducted in a hospital. The keywords used to search the database wer

The Effectiveness of Health Management-Assisted Technology on Glycated Hemoglobin Levels in Patients with Type 2 Diabetes Mellitus: Meta-Analysis

Background: Given the number of patients failing to achieve control of Diabetes Mellitus (DM), it causes an increase in the incidence of DM complications. Along with the rapid deve­lopment of technology in this era, this study aimed to prove the effectiveness of technology-based health management compared to usual treatment for levels glycated hemoglobin (HbA1c) in type 2 diabetes mellitus patients.Subjects and Method: This was a meta-ana­lysis using a randomized controlled trial. Arti­cles were obtained from PubMed, Google Scholar, and ResearchGate databases. The arti­cles used in this study were those published from 2012-2021. The search article was carried out by considering the eligibility of the criteria determined using the PICO model. Population: type 2 DM patients (HbA1c>7%), Intervention: health management-assisted technology, Com­parison: usual care Outcome: HbA1c levels. There were 10 articles used with a sample size of 1693 people who were divided into two groups (845 people in the health management-assisted technology group and 848 people in the group usual care). Articles were analyzed using Review Manager 5.3 Appli­cation to determine the Standard Mean Diffe­rence (SMD) and heterogeneity of the study sample.Results: From 10 articles that were processed using RevMan 5.3, significant results were obtained, this is indicated by the overall effect (diamond) which does not touch the vertical line H0 (d= 0) and can also be seen from the 95% CI range of -0.62 to -0.13 which shows significant because it does not pass the number 0 (SMD= -0.37; 95% CI= -0.62 to -0.13; p= 0.003). The heterogeneity of the research data shows I2 = 82% so that the distribution of the data is very heterogeneous (random effects model).Conclusion: Using technology to help health management of patients with type 2 diabetes mellitus can reduce HbA1c levels compared to usual care.Keywords: Health management, technology, diabetes mellitus, HbA1cCorrespondence: Fajar Novianto. Center for Research and Deve­lopment of Medicinal Plants and Traditional Medicine, National Institute of Health of Health, Jl. Raya Lawu No. 11 Karanganyar, Central Java. Email: dr.fajarnovianto@gmail.­com.Journal of Health Policy and Management (2021), 06(02): 81-93https://doi.org/10.26911/thejhpm.2021.06.02.01

The Effectiveness of Ivermectin on the Risk of Mortality in COVID-19 Patients: A Meta Analysis

Background: The Coronavirus Disease 2019 (COVID-19) has become the highest priority of global pandemic. New and repurposed drugs are being tested on mild to moderate levels of COVID-19 to help suppress transmission of the virus. Ivermectin is one of the repurposed drugs with known safety records with more than 2.5 billion doses dispensed in the past. This study aims to estimate the effectiveness of ivermectin in reducing the risk of mortality in COVID-19 patients based on the results of a number of previous similar studies. Subjects and Method: This study is a systematic review and meta-analysis. This study used secondary data in the form of data from previous study results. A systematic and comprehensive database search was carried out through several databases including: PubMed, Science Direct, Google Scholar, and Springer Link. Analysis of this study was using RevMan 5.3 software. This study used the eligibility criteria with the PICO model, populations: covid-19 patients, intervention: ivermectin administration, comparison: patients without ivermectin, outcome: mortality in COVID-19 patients. The inclusion criteria used were full paper in English and Indonesian with a randomized controlled trial, including the number of deaths, and the primary study was conducted in a hospital. The keywords used to search the database wer